Dr. Chau on the Tolerability of Ramucirumab Plus Pembrolizumab in Gastric/GEJ Cancer

Ian Chau, MD
Published: Monday, Jan 22, 2018



Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the tolerability of ramucirumab (Cyramza) plus pembrolizumab (Keytruda) in gastric or gastroesophageal (GEJ) cancer.

In a phase I study of the combination of ramucirumab plus pembrolizumab in patients with treatment-naïve gastric or GEJ adenocarcinoma, safety and anti-tumor activity were evaluated. Ramucirumab was administered at 8 mg/kg on days 1 and 8, and pembrolizumab at 200 mg on day 1 of week 3. PD-L1 status was assessed by DAKO PD-L1 22C3 IHC pharmDx assay.

Of 28 patients, 7 achieved an objective response, 6 that were positive for PD-L1 and 1 that was not. Additionally, median progression-free survival was 5.3 months (95% CI 3.2-1.1). At the time of data presentation at the 2018 Gastrointestinal Cancers Symposium, median overall survival had not been reached.

This combination is very well tolerated, says Chau, with very few grade 3/4 toxicities, with the most common grade 3 toxicity being hypertension. Compared to standard cytotoxic chemotherapy where there is a high rate of grade 3/4 side effects, this is a well-tolerated combination for the treatment of patients with gastric or GEJ cancer, Chau concludes. This trial is currently ongoing.


Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the tolerability of ramucirumab (Cyramza) plus pembrolizumab (Keytruda) in gastric or gastroesophageal (GEJ) cancer.

In a phase I study of the combination of ramucirumab plus pembrolizumab in patients with treatment-naïve gastric or GEJ adenocarcinoma, safety and anti-tumor activity were evaluated. Ramucirumab was administered at 8 mg/kg on days 1 and 8, and pembrolizumab at 200 mg on day 1 of week 3. PD-L1 status was assessed by DAKO PD-L1 22C3 IHC pharmDx assay.

Of 28 patients, 7 achieved an objective response, 6 that were positive for PD-L1 and 1 that was not. Additionally, median progression-free survival was 5.3 months (95% CI 3.2-1.1). At the time of data presentation at the 2018 Gastrointestinal Cancers Symposium, median overall survival had not been reached.

This combination is very well tolerated, says Chau, with very few grade 3/4 toxicities, with the most common grade 3 toxicity being hypertension. Compared to standard cytotoxic chemotherapy where there is a high rate of grade 3/4 side effects, this is a well-tolerated combination for the treatment of patients with gastric or GEJ cancer, Chau concludes. This trial is currently ongoing.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x